Tradestie Institutional Equity Comparison Engine

CELU vs LVTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LVTX Overall Edge

LVTX Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LAVA Therapeutics N.V. Ordinary Shares (LVTX) driven by superior Growth & Margin, Momentum & Technical while CELU counters with relative strength in Options & Structure. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus LVTX at N/M Forward P/E and -431.9% operating margin (+1313.6% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against LVTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CELU N/M vs LVTX N/M Fwd P/E
Growth & Margin Winner LVTX
Op Margin -254.0% vs -431.9% ยท YoY -5.3% vs +1313.6%
Momentum & Technical Winner LVTX
1Y -72.6% vs +17.6% ยท 52W Pos 2% vs 77%
Options & Structure Winner CELU
BREAKDOWN (50th %ile IV) vs UNCLASSIFIED (N/A IV)
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
1M Return -55.9%
1Y Return -72.6%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
LVTX NASDAQ
LAVA Therapeutics N.V. Ordinary Shares
Pharmaceutical Preparations
$1.74
-3.87% 1D
Market Cap $45.8M
1M Return +6.75%
1Y Return +17.57%
Forward P/E N/M
Unified AI Score
67.0 / 100 BUY
Tech 75.0 Fund 63.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CELU -72.6% LVTX +17.57% Spread: +5.05 pp (CELU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CELU TTM Op. Margin: -254.0% LVTX TTM Op. Margin: -431.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELU vs LVTX. Trailing 12-month operating profitability (CELU -254.0% vs LVTX -431.9%) and valuation multiples (CELU N/M vs LVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CELU (1) vs LVTX (7)
Institutional Metric CELU LVTX Criterion Row Winner
Market Capitalization Scale $15.2M $45.8M Larger Scale LVTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -5.3% +1313.6% Higher Growth LVTX
Operating Margin (TTM) Profitability -254.0% -431.9% Higher Margin CELU
Net Profit Margin Profitability -245.7% 0.0% Higher Margin LVTX
Return on Equity (ROE) Capital Efficiency -6367.2% -101.5% Higher ROE LVTX
52-Week Range Position Momentum 2% ($0โ€“$3) 77% ($1โ€“$2) Stronger Trend LVTX
Beta / 30D Volatility Risk Regime 2.01ฮฒ ยท 135% Vol -0.02ฮฒ ยท 49% Vol Lower Realized Risk LVTX
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 67.0 / 100 (BUY) Higher Composite LVTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CELU vs LVTX Buy Guide
CELU BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LVTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LVTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CELU nor LVTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.